Navigation Links
Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkin's Lymphoma at
Date:12/7/2012

Abstract #: 2768
Lead Author: Christopher Brooks, Ph.D., Stemline Therapeutics, Inc.
Session: 625. Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Poster II
Date/Time: Sunday, December 9, 2012; 6:00 – 8:00pm ET
Location: Hall B1-B2 (Georgia World Congress Center)

A copy of the above referenced abstracts can be viewed online through the ASH website at www.hematology.org.

About Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Among Stemline's drug candidates are SL-401 and SL-701, both of which have demonstrated single agent clinical activity in Phase 1/2 studies of advanced cancer patients. In a multicenter Phase 1/2 trial in patients with advanced acute myeloid leukemia (AML) and other hematologic malignancies including blastic plasmacytoid dendritic cell neoplasm (BPDCN), SL-401 demonstrated single agent activity, including durable complete responses (CRs), and an overall survival (OS) improvement relative to historical data in the most heavily pretreated AML patients. SL-401 also induced two additional CRs in patients with relapsed/refractory BPDCN, a rare lymphoma. In addition, SL-401 was well-tolerated and was not toxic to the bone marrow. SL-401 is being advanced into later stage trials in advanced BPDCN and AML. In Phase 1/2 trials, Stemline's second clinical stage therapeutic, SL-701, has demonstrated single agent activity including durable CRs and partial responses (PRs) in adult patients with refractory or recurrent glioblastoma and pediatric patients with malignant glioma, as well as an OS benefit in adult patients with refractory or recurrent glioblastoma compared with historical data. SL-701 is now poised for later stage trials in pediatric and adult patients with advanced brain cancer. Stemline is also
'/>"/>

SOURCE Stemline Therapeutics, Inc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Stemline Therapeutics, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference
2. Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
3. Cell Therapeutics, Inc. (CTI) to Present at Jefferies 2012 Global Healthcare Conference
4. Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 1
5. Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones
6. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
7. ISPE Announces 2012 Award Winners at Global Annual Meeting
8. Sequenom, Inc. Announces Issuance Of Patent For Methods Of Detecting Fetal Aneuploidy
9. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
10. T1D Exchange Announces Appointment of Dana Ball as Chief Executive Officer
11. Saladax Biomedical, Inc. Announces the Formation of a CLIA Laboratory As Part of the Companys Commercialization Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2014)... PLANTATION, Fla. , July 18, 2014  Neurotrope, ... 2014,  its Board of Directors appointed Co-Chairmen Charles ... Co-Chief Executive Officers on an interim basis, effective immediately. ... , who is no longer Chief Executive Officer of ... or the Company and whose employment agreement with Neurotrope ...
(Date:7/18/2014)... CHICAGO, Ill. , July 18, 2014 ... an infographic highlighting AbbVie and Shire,s complementary ... combination. A copy of the ... website at:  http://www.abbvieinvestor.com/phoenix.zhtml?c=251551&p=irol-disclaimer-documents ... Takeover Code, a copy of this announcement ...
(Date:7/18/2014)... Provia Laboratories announces the addition of Dr. Jim ... Vaught has worked in the field of biorepository and ... of the founding members of ISBER – the International ... he served as its second president, and 15 years ... Vaught began working with the National Institutes of Health ...
(Date:7/17/2014)... Australia , July 17, 2014  Prana Biotechnology ... provided an update on its clinical development program for ... the Florey Institute of Neuroscience and Mental Health, The ... Phase 2 IMAGINE and EURO trials in his presentation ... Copenhagen, Denmark . The presentation is ...
Breaking Biology Technology:Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 2Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 3Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 4NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 2NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 3NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 4NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 5NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 6NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 7Dr. Jim Vaught, Ph.D., Former Chief of BBRB, Joins Provia Laboratories as Advisory Board Member 2Dr. Jim Vaught, Ph.D., Former Chief of BBRB, Joins Provia Laboratories as Advisory Board Member 3Prana Alzheimer's disease Development Program update 2Prana Alzheimer's disease Development Program update 3Prana Alzheimer's disease Development Program update 4Prana Alzheimer's disease Development Program update 5
... Do the principles of quantum mechanics apply to biological ... Institute,s Chemical Physics Department (Faculty of Chemistry), both biologists ... to be like apples and oranges. But research he ... in Science , definitively shows that a biological ...
... China March 31, 2011 /PRNewswire-Asia/ -- Tiens Biotech Group (USA), ... ), a company dedicated to the research, development, ... and dietary supplements, today announced financial results for ... revenue was $41.3 million, compared to $62.0 million for 2009. ...
... March 31, 2011 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: ... developer, manufacturer and distributor of probiotics products in China, ... sales order from its newly signed U.S. customer. ... first sales order, and formally entered into its agreement ...
Cached Biology Technology:Biological molecules select their spin 2Tiens Biotech Group (USA) Reports 2010 Results 2Tiens Biotech Group (USA) Reports 2010 Results 3Tiens Biotech Group (USA) Reports 2010 Results 4Tiens Biotech Group (USA) Reports 2010 Results 5Tiens Biotech Group (USA) Reports 2010 Results 6Tiens Biotech Group (USA) Reports 2010 Results 7China-Biotics Receives First U.S. Sales Order 2China-Biotics Receives First U.S. Sales Order 3
(Date:7/22/2014)... SHELTON, Conn. , July 22, 2014 /PRNewswire/ ... on the growing m-commerce market, announces its next generation ... weekly 30-minute consumer oriented television show that airs ... Network. NewsWatch regularly features top ... on July 31st on the History Channel (6:00-6:30am ...
(Date:7/22/2014)... of immune cell widely believed to exacerbate chronic ... multiple sclerosis (MS), can actually protect the brain ... the progression of neurodegenerative diseases, according to Cleveland ... Nature Communications . , The research team, ... Department of Neurosciences at Cleveland Clinic,s Lerner Research ...
(Date:7/22/2014)... the the genus of planthopper known as Conosimus, which ... recently discovered in the southern part of the Iberian ... of it appears in the open-access Journal of ... new species, Conosimus baenai , has been named ... to the taxonomy of Iberian Hemiptera. , Conosimus ...
Breaking Biology News(10 mins):NXT-ID's Next Generation Wocket Smart Wallet to be Featured on NewsWatch, Airing on History Channel, FYI Network and ION Network 2NXT-ID's Next Generation Wocket Smart Wallet to be Featured on NewsWatch, Airing on History Channel, FYI Network and ION Network 3Cleveland Clinic researchers discover neuroprotective role of immune cell 2
... studies continue to validate the use of probiotics to ... for probiotics indicates that the U.S. healthcare community and ... microorganisms. However, because most probiotics are classified as dietary ... individual needs can be challenging. And, as the ...
... The Seventh Annual Symposium on Predictive Health, to ... on health and the human microbiome. The human microbiome ... and viruses, which reside throughout the body. Study ... attention across the United States, including a major federal ...
... of Atlantic salmon (Salmo salar), which have been ... new challenges in the Gulf of Maine, where ... new predators along altered migration routes are affecting ... in the journal Fisheries Management and Ecology, ...
Cached Biology News:As probiotics use grows for gut health, VSL#3 has designations for specific GI issues 2As probiotics use grows for gut health, VSL#3 has designations for specific GI issues 3Predictive health symposium will focus on human microbiome 2Environmental conditions and predators affect Atlantic salmon survival in the Gulf of Maine 2
...
... catalyzes the formation of phosphodiester bonds in ... with 3' hydroxyl and 5' phosphate termini. ... ligation which can be performed in 5 ... substrates for this enzyme. A T4 ...
Porcine Aortic Endothelial Cells (PAOEC) (>500,000 cells)...
Bovine Endometrium Epithelial Cells (BEnEpC) (>500,000 cells)...
Biology Products: